Getting the Comparison Right
The "Mounjaro vs. Ozempic" comparison is everywhere—but it’s technically comparing two diabetes medications being discussed for weight loss. The accurate comparison for weight management is Zepbound vs. Wegovy:
| Diabetes Product | Weight Loss Product | Active Ingredient |
|---|---|---|
| Mounjaro | Zepbound | Tirzepatide |
| Ozempic | Wegovy | Semaglutide |
The weight loss products have higher maximum doses and FDA approval for obesity—making them the appropriate choice for weight management. That said, the clinical data comparing these molecules is instructive.
Important distinction: Mounjaro and Ozempic are FDA-approved for type 2 diabetes only, not weight loss. For obesity treatment, compare Zepbound vs Wegovy.
Different Mechanisms of Action
| Feature | Tirzepatide (Mounjaro/Zepbound) | Semaglutide (Ozempic/Wegovy) |
|---|---|---|
| Receptor targets | Dual: GIP + GLP-1 | Single: GLP-1 only |
| Appetite suppression | Through both GIP and GLP-1 pathways | Through GLP-1 pathway |
| Insulin sensitization | Enhanced via dual receptor activation | Via GLP-1 pathway |
| Gastric emptying | Significantly delayed | Significantly delayed |
| Fat tissue effects | GIP may improve adipose function | Indirect through weight loss |
The additional GIP receptor activation is believed to be the key differentiator, providing an additive metabolic effect beyond what GLP-1 alone achieves.
Tirzepatide doesn't simply do the same thing as semaglutide but stronger. It works through an additional pathway—GIP—that influences metabolism, appetite, and body composition through complementary mechanisms.
Head-to-Head & Cross-Trial Data
SURPASS-2: Direct Comparison (Diabetes)
| Metric | Tirzepatide 15 mg | Semaglutide 1 mg |
|---|---|---|
| HbA1c reduction | -2.46% | -1.86% |
| Weight loss | -12.4 kg | -6.2 kg |
| % achieving HbA1c <7% | 92% | 81% |
Cross-Trial Comparison (Weight Management)
| Metric | Tirzepatide 15 mg (SURMOUNT-1) | Semaglutide 2.4 mg (STEP 1) |
|---|---|---|
| Average weight loss | 22.5% | 14.9% |
| % losing >20% | 57% | 32% |
| % losing >10% | ~90% | ~69% |
Note: Cross-trial comparisons have limitations—different patient populations, sites, and protocols. A head-to-head weight management trial would be more definitive.
Side Effect Comparison
GI side effects are broadly similar between the two medications:
- Nausea, diarrhea, and vomiting rates are comparable in head-to-head data
- Tirzepatide’s GIP component may offer some GI tolerability advantage
- Both follow the same pattern: worst during titration, improving with adaptation
- Discontinuation rates are similar (4–7% for both)
Which Is Better for You?
"Better" depends on individual factors:
- Tirzepatide may be preferred when: Maximum weight loss is the priority; dual mechanism is appropriate; Zepbound is covered by insurance
- Semaglutide may be preferred when: Wegovy is better covered by your insurance; you’ve already responded well to semaglutide; cardiovascular risk reduction is a primary goal (SELECT trial data)
- Both are excellent options. Either represents a dramatic advance over previous weight loss medications. The "best" medication is the one you can access, afford, and tolerate
The PEAK Approach
At PEAK, medication selection is individualized based on:
- Your medical history and metabolic profile
- Insurance coverage and cost considerations
- Personal response to medication (some patients respond better to one than the other)
- Prior medication history
We prescribe both Wegovy and Zepbound—always the FDA-approved weight management products, not diabetes medications used off-label.
Boxed warning — thyroid C-cell tumors: GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) carry an FDA boxed warning for thyroid C-cell tumors observed in rodent studies. They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Tell your provider immediately if you notice a lump in your neck, difficulty swallowing, or persistent hoarseness.
